Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Takeda antihypertensive

The US Food and Drug Administration has approved Takeda's Edarbi tablets to treat high blood pressure in adults

The US Food and Drug Administration (FDA) has approved Takeda's Edarbi tablets (azilsartan medoxomil) to treat high blood pressure in adults, either as monotherapy or in combination with other antihypertensives.

Phase III clinical studies of the angiotensin II receptor blocker (ARB) found that it was more effective at lowering blood pressure than the highest approved doses of Novartis' Diovan (valsartan) or Daiichi Sankyo's Benicar (olemesartan). Analysts polled by Thomson Reuters predicted the Takeda drug could have annual sales of $733m in 2014.

Edarbi will be available in 80mg and 40mg doses, with the recommended dose set at 80mg once daily. The 40mg dose will be sold for patients who are treated with high-dose diuretics taken to reduce salt in the body.

The drug will carry a boxed warning, which is the strongest warning that the FDA can require, stating that it should not be taken during pregnancy because use during the second or third trimester can cause foetal injury or death.

Takeda submitted the US new drug application for Edarbi in April 2010. This month, the company submitted an additional application to the FDA for a fixed-dose combination of Edarbi plus chlorthalidone, a long-acting diuretic that is available as a generic from a number of manufacturers. The product is the first combination of chlorthalidone and an ARB to be submitted for marketing in the US.

28th February 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics